Barclays analyst Carter Gould lowered the firm’s price target on Travere Therapeutics to $12 from $31 and keeps an Overweight rating on the shares following the PROTECT study data. The analyst expects “near-term choppiness” into the atrasentan data, but sees a path to shares moving higher into the end of 2023 assuming the pre-new drug application FDA feedback is supportive.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- William Blair downgrades Travere on increased Filspari risk after trial miss
- Travere Therapeutics downgraded to Market Perform from Outperform at William Blair
- Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
- Travere announces confirmatory data from Phase 3 PROTECT study of FILSPARI
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)